Bionxt launched the final animal study needed to prepare for human testing of BNT23001, its under-the-tongue version of ...
Detailed price information for Aspire Biopharma Holdings Inc (ASBP-Q) from The Globe and Mail including charting and trades.
VANCOUVER,BC / ACCESS Newswire / September 29, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...
Changes strategically aligned to support planned launch of Anaphylm™ (dibutepinephrine) Sublingual Film, if approved by the FDA, and to ...
Everyday Health on MSN
Are Compounded GLP-1 Drugs Banned?
The availability of compounded GLP-1 drugs shifted after the FDA changed their regulations in April 2025. Here’s what to know.
H1 2026: Finalize formulation and manufacture test product. H1 2026 Initial Phase 1 pharmacokinetic clinical cross-over study. "Our pipeline is focused on research in therapeutic areas where we can ...
H2 2025: Request meeting with FDA to discuss 505(b)(2) pathway. H2 2025: Target submission of New Drug Application (NDA). Sublingual ED medication H1 2026: Finalize formulation and manufacture test ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback